Australia's most trusted
source of pharma news
Wednesday, 22 January 2025
Posted 21 January 2025 PM
The TGA has strengthened the label of montelukast-containing medicines to warn of neuropsychiatric events, bringing the Australian Product Information (PI) and Consumer Medicine Information (CMI) in line with international regulatory advice.
The heavily genericised oral medicine is used to prevent and treat chronic asthma in adults and children aged two years and older, and for symptomatic seasonal allergic rhinitis (hay fever).
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.